Completed PHASE3 INTERVENTIONAL NCT00165685

A Comparative Study of KES524 in Patients With Obesity Disease

A Double-Blind, Placebo-Controlled, Comparative Study of KES524 in Patients With Obesity Disease

Sponsor: Eisai Limited

Conditions Obesity

Interventions Sibutramine Hydrochloride Monohydrate

Updated 6 times since 2017 Last updated: Jan 28, 2010 Started: Jul 31, 2004 Primary completion: Mar 31, 2007 Completion: Mar 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Obesity, this trial is completed. The trial is conducted by Eisai Limited and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Limited

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chiba, Japan , Chiyoda-ku, Japan , Chuo-ku, Japan , Fukushima, Japan , Hachiōji, Japan , Hitachiota, Japan , Itabashi-ku, Japan , Kashiwa, Japan , Kōriyama, Japan , Maebashi, Japan and 8 more locations